Ivd Infectious Disease Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends 2026-2030

Infectious disease IVD products include immunoassays, molecular diagnostics, microbiology systems, and point-of-care rapid tests used to identify conditions such as HIV, hepatitis, tuberculosis, respiratory infections, and sexually transmitted diseases. The market has experienced elevated demand since the COVID-19 pandemic highlighted the critical need for scalable, accurate diagnostic infrastructure. While the pandemic temporarily inflated 2020-2022 figures, the market has since adjusted to a more normalized growth trajectory as routine testing volumes stabilize and new product innovations emerge.

• •Market size estimated at approximately $26.1 billion in 2025, with projections to reach roughly $28-30 billion by 2030 at a 2.5-2.7% CAGR
• •Encompasses laboratory-based and point-of-care testing for bacterial, viral, fungal, and parasitic infections
• •COVID-19 pandemic drove short-term market expansion; post-pandemic normalization continues with steady demand from endemic infectious diseases

The rising global burden of infectious diseases, including tuberculosis, HIV/AIDS, hepatitis, and emerging viral threats, remains a core growth engine, particularly in low- and middle-income countries with limited healthcare access. Aging populations and increasing prevalence of chronic conditions that compromise immune function further amplify demand for infectious disease screening. Additionally, growing adoption of molecular diagnostic technologies, which offer faster turnaround times and higher sensitivity compared to traditional methods, is reshaping product preferences among laboratories and clinicians.

• •Growing prevalence of HIV, tuberculosis, and hepatitis, combined with emerging infectious disease threats, drives sustained testing demand
• •Technological shift toward molecular diagnostics and point-of-care testing accelerates adoption in both clinical and non-clinical settings
• •Government and institutional investments in pandemic preparedness and surveillance infrastructure support market expansion

The infectious disease IVD market is typically segmented by product type, immunoassays, molecular diagnostics, microbiology, and others, as well as by application, including hospital-based testing, diagnostic laboratories, and point-of-care settings. North America currently holds the largest market share due to advanced healthcare infrastructure, high testing volumes, and strong reimbursement frameworks, while Europe represents a significant and mature market. The Asia-Pacific region is projected to be the fastest-growing segment, driven by improving healthcare access, rising disease awareness, and increasing investment in diagnostic capacity across countries including China, India, and Southeast Asian nations.

• •North America leads in market share, supported by established laboratory infrastructure and favorable reimbursement policies
• •Asia-Pacific is the fastest-growing region, driven by expanding healthcare access, population growth, and rising infectious disease screening rates
• •Product segments include immunoassays (largest share), molecular diagnostics (fastest growing), and microbiology testing

What are the recent trends and outlook?

The market is expected to see continued innovation in multiplex testing, which enables simultaneous detection of multiple pathogens from a single sample, improving efficiency and reducing costs. Artificial intelligence and digital integration in diagnostic workflows are emerging as key differentiators, supporting faster interpretation and decision-making. Over the longer term, growing emphasis on antimicrobial stewardship and the need to combat antibiotic resistance are likely to drive demand for precise, rapid diagnostics that guide targeted treatment decisions.

• •Multiplex and syndromic panel testing gaining adoption to enable broad-pathogen detection from a single sample
• •Point-of-care and decentralized testing models expanding as healthcare systems prioritize rapid, accessible diagnostics
• •Antimicrobial resistance concerns and stewardship programs increasingly driving investment in rapid infectious disease diagnostics